Abstract
Parkinson’s disease (PD) is a major cause of morbidity and mortality among older individuals. Several researchers have suggested that iron chelators which cross the blood-brain barrier (BBB) might have clinical efficacy in treating PD. Therefore, efforts are made not only in order to improve the effect of L-dopa but also to introduce drugs which provide anti-parkinsonian and neuroprotective effects. In this study, quercetin, a flavonoid, exhibited noticeable neuroprotective effects via iron induced-oxidative stress-dependent apoptotic pathways. Our results suggested that quercetin significantly decreased the catalepsy and exhibited neuroprotective effects in rotenone-induced Parkinson. A model of rotenone-induced Parkinsonism in rats produced the decrease in glutathione, SOD, catalase, and serum iron concentration and the increase in H2O2 and lipid peroxidation activity. Quercetin efficiently halted the deleterious toxic effects of L-dopa, revealing normalization of catalepsy and rotarod score, in addition to amelioration of neurochemical parameters, indicating benefit of both symptomatic and neuroprotective therapies. In silico molecular docking studies have also shown that quercetin could be an ideal potential drug target for aromatic L-amino acid decarboxylase and human catechol-O-methyltransferase. In conclusion, quercetin possesses strong iron-chelating abilities and could be recommended as a disease-modifying therapy when administered in combination with L-dopa, early on in the course of Parkinson’s disease.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aguilera G, Colín-González AL, Rangel-López E, Chavarría A, Santamaría A (2018) Redox signaling, neuroinflammation, and neurodegeneration. Antioxid Redox Signal 28(18):1626–1651
Boyina HK, Jerald MK, Bharatraj DK, Diwan PV (2018) Influence of fisetin combined with hesperidin on chronic mild hyperhomocysteinemia induced cognitive dysfunction and oxidative stress in wistar rats. Pharma Nutrition 6(3):125–136
Castañeda-Arriaga R, Pérez-González A, Reina M, Alvarez-Idaboy JR, Galano A (2018) Comprehensive investigation on the antioxidant and pro-oxidant effects of phenolic compounds: a double-edged sword in the context of oxidative stress? J Phys Chem B 122(23):6198–6214
Cenci MA, Crossman AR (2018) Animal models of l-dopa-induced dyskinesia in Parkinson’s disease. Mov Disord 33(6):889–899
Chauhan A, Jeans AF (2015) Is Parkinson’s disease truly a prion-like disorder? An appraisal of current evidence. Neurol Res Int 2015:345285
Costall B, Naylor R (1974) On catalepsy and catatonia and the predictability of the catalepsy test for neuroleptic activity. Psychopharmacologia 34(3):233–241
El-Horany HE, El-latif RNA, ElBatsh MM, Emam MN (2016) Ameliorative effect of quercetin on neurochemical and behavioral deficits in rotenone rat model of Parkinson’s disease: modulating autophagy (quercetin on experimental Parkinson’s disease). J Biochem Mol Toxicol 30(7):360–369
Erboga M, Aktas C, Erboga ZF, Donmez YB, Gurel A (2015) Quercetin ameliorates methotrexate-induced renal damage, apoptosis and oxidative stress in rats. Ren Fail 37(9):1492–1497
Ghiglieri V, Calabrese V, Calabresi P (2018) Alpha-Synuclein: from early synaptic dysfunction to neurodegeneration. Front Neurol 9:295
Gould FD, Gross A, German RZ, Richardson JR (2018) Evidence of oropharyngeal dysfunction in feeding in the rat rotenone model of Parkinson’s disease. Parkinson’s Disease.11;2018:6537072
Gowthami N, Sunitha B, Kumar M, Prasad TK, Gayathri N, Padmanabhan B, Bharath MS (2018) Mapping the protein phosphorylation sites in human mitochondrial complex I (NADH: ubiquinone oxidoreductase): a bioinformatics study with implications for brain aging and neurodegeneration. J Chem Neuroanat 95:13–28
Hemanth Kumar B, Arun Reddy R, Mahesh Kumar J, Dinesh Kumar B, Diwan PV (2016) Effects of fisetin on hyperhomocysteinemia-induced experimental endothelial dysfunction and vascular dementia. Can J Physiol Pharmacol 95(1):32–42
Hemanth Kumar B, Dinesh Kumar B, Diwan PV (2017) Hesperidin, a citrus flavonoid, protects against l-methionine-induced hyperhomocysteinemia by abrogation of oxidative stress, endothelial dysfunction and neurotoxicity in Wistar rats. Pharm Biol 55(1):146–155
Jankovic J (2008) Parkinson’s disease: clinical features and diagnosis. Journal of Neurology, Neurosurgery & Psychiatry 79(4):368–376
Jeon SJ, Kim MO, Ali-Shah F, Koh PO (2017) Quercetin attenuates the injury-induced reduction of γ-enolase expression in a middle cerebral artery occlusion animal model. Lab Anim Res 33(4):308
Kabel AM, Omar MS, Alhadhrami A, Alharthi SS, Alrobaian MM (2018) Linagliptin potentiates the effect of l-dopa on the behavioural, biochemical and immunohistochemical changes in experimentally-induced parkinsonism: role of toll-like receptor 4, TGF-β1, NF-κB and glucagon-like peptide 1. Physiol Behav 188:108–118
Keddy PG, Dunlop K, Warford J, Samson ML, Jones QR, Rupasinghe HP, Robertson GS (2012) Neuroprotective and anti-inflammatory effects of the flavonoid-enriched fraction AF4 in a mouse model of hypoxic-ischemic brain injury. PLoS One 7(12):e51324
Kelly MA, Rubinstein M, Phillips TJ, Lessov CN, Burkhart-Kasch S, Zhang G, Bunzow JR, Fang Y, Gerhardt GA, Grandy DK, Low MJ (1998) Locomotor activity in D2 dopamine receptor-deficient mice is determined by gene dosage, genetic background, and developmental adaptations. J Neurosci 18(9):3470–3479
Li C, Tang B, Feng Y, Tang F, Pui-Man Hoi M, Su Z, Ming-Yuen Lee S (2018) Pinostrobin exerts neuroprotective actions in neurotoxin-induced Parkinson’s disease models through Nrf2 induction. J Agric Food Chem 66(31):8307–8318
Michel PP, Hirsch EC, Hunot S (2016) Understanding dopaminergic cell death pathways in Parkinson disease. Neuron 90(4):675–691
Ruddarraju RR, Kiran G, Murugulla AC, Maroju R, Prasad DK, Kumar BH, Bakshi V, Reddy NS (2019) Design, synthesis and biological evaluation of theophylline containing variant acetylene derivatives as α-amylase inhibitors. Bioorg Chem 92:103120
Sarubbo F, Esteban S, Miralles A, Moranta D (2018) Effects of resveratrol and other polyphenols on Sirt1: relevance to brain function during aging. Curr Neuropharmacol 16(2):126–136
Sharma N, Nehru B (2013) Beneficial effect of vitamin E in rotenone induced model of PD: behavioural, neurochemical and biochemical study. Exp Neurobiol 22(3):214–223
Sharma S, Kumar P, Deshmukh R (2018) Neuroprotective potential of spermidine against rotenone induced Parkinson’s disease in rats. Neurochem Int 116:104–111
Shi GJ, Li Y, Cao QH, Wu HX, Tang XY, Gao XH, Yu JQ, Chen Z, Yang Y (2019) In vitro and in vivo evidence that quercetin protects against diabetes and its complications: A systematic review of the literature. Biomed Pharmacother 109:1085–1099
Surmeier DJ (2018) Determinants of dopaminergic neuron loss in Parkinson’s disease. FEBS J 285:3657
Yan X, Uronen R-L, Huttunen HJ (2018) The interaction of α-synuclein and Tau: a molecular conspiracy in neurodegeneration? Semin Cell Dev Biol.9:S1084-9521(17)30389-0
Acknowledgments
We thank Dr. P. Rajeshwar Reddy (Chairman, Anurag Group of Institutions) and Dr. Prakash V Diwan (Director, Anurag Group of Institutions) for providing research facilities to carry out this work.
Conflict of Interest
The authors declare no conflict of interest.
Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this paper
Cite this paper
Boyina, H.K. et al. (2020). In Silico and In Vivo Studies on Quercetin as Potential Anti-Parkinson Agent. In: Vlamos, P. (eds) GeNeDis 2018. Advances in Experimental Medicine and Biology, vol 1195. Springer, Cham. https://doi.org/10.1007/978-3-030-32633-3_1
Download citation
DOI: https://doi.org/10.1007/978-3-030-32633-3_1
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-32632-6
Online ISBN: 978-3-030-32633-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)